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Abstract: The total synthesis of two decahydroquinoline poison frog alkaloids ent-cis-195A and
cis-211A were achieved in 16 steps (38% overall yield) and 19 steps (31% overall yield), respectively,
starting from known compound 1. Both alkaloids were synthesized from the common key intermediate 11 in a divergent fashion, and the absolute stereochemistry of natural cis-211A was determined to
be 2R, 4aR, 5R, 6S, and 8aS. Interestingly, the absolute configuration of the parent decahydroquinoline
nuclei of cis-211A was the mirror image of that of cis-195A, although both alkaloids were isolated
from the same poison frog species, Oophaga (Dendrobates) pumilio, from Panama.
Keywords: decahydroquinoline; poison frog alkaloid; cis-195A; cis-211A

published maps and institutional affiliations.

1. Introduction

Copyright: © 2021 by the authors.
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The skin extracts of Neotropical poison frogs contain a variety of lipophilic alkaloids,
and over 800 alkaloids have been isolated or detected to date [1]. Many of these alkaloids
show remarkable biological activities on the nervous system such as nicotinic acetylcholine
receptors [2,3]. Methods for chemical synthesis of poison frog alkaloids are needed to investigate the biological activities of poison frog alkaloids, as only minute amounts of natural
alkaloids can be obtained from skin extracts [1]. Decahydroquinolines are a relatively large
subgroup of poison frog alkaloids, and over 50 types have been detected. Among them,
the alkaloid cis-195A is the parent member of this class that was originally isolated from
a Panamanian population of Oophaga (Dendrobates) pumilio in 1969 [4]. The structure and
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Figure 1. Structures of cis-195A and cis-211A.

Figure 1. Structures of cis-195A and cis-211A.
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Finally, global hydrogenation of 11 and deprotection of the methyl carbamate moiety
in 12 using TMSI in CHCl3 at 50 °C provided ent-cis-195A, as shown in Scheme 2. The 1H
and 13C-NMR spectra of synthetic ent-cis-195A were in good agreement with those reported in the literature [22].
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Swern, a SO3 -pyridine complex, PCC, PDC, DMP, or TPAP were not successful, and the
starting material was recovered. Only oxidation using AZADOL® [41] proceeded smoothly
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to yield the desired ketone 19 in good yield. In addition, the AZADOL® oxidation of the
mixture of 16 and 17 afforded the ketones 19 and 20 in 34% and 66% yield, respectively,
which could be easily separated by column chromatography. Thus, we succeeded to
obtain the ketone 19 from 13 in 64% (49% + 15%) overall yield, as shown in Scheme 3.
The conformation of ketone 19 is depicted in 19-A. The reduction of 19 from the concave
face was needed to obtain the desired alcohol 16. We expected that the reduction of 19
would proceed from the concave face, as shown in 19-A, because of the steric hindrance
of the α-axial methyl group. However, the use of a small reducing agent like NaBH4 or
LiAlH4 reduced 19 from the convex face to afford 15 as the sole product. To secure the
reduction from the concave face, we tried the large reducing agent L-Selectride® ; however,
the reduction did not proceed, and only ketone 19 was recovered. Fortunately, SuperHydride® , a moderately sized reducing agent, was the best match for this substrate, and
the reduction proceeded from the concave face to provide the desired alcohol 16 as the
major product (16:15 = 9:1). The final deprotection of the urethane moiety in 16 was also
troublesome. First, we applied the same reaction conditions used for ent-cis-195A (TMSI in
refluxing CHCl3 ) to cleave the methyl carbamate; however, the reaction did not proceed.
Then, other reaction conditions, such as the use of n-PrSLi/HMPA or KOH/i-PrOH in a
sealed tube at 130 ◦ C, resulted in the recovery of the starting material. Finally, we used
Molecules 2021, 26, x FOR PEER REVIEW
of 17
TMSI in refluxing MeCN, and the reaction proceeded cleanly to yield cis-211A, as 5shown
in Scheme 3.

Scheme3.3.Total
Totalsynthesis
synthesis of
of cis-211A.
cis-211A.
Scheme

The 1H- and 13C-NMR spectra of synthetic cis-211A were in good agreement with the
reported values [23]. The absolute stereochemistry of natural cis-211A was determined
unambiguously by the present synthesis to be 2R, 4aR, 5R, 6S, and 8aS by comparison of
the optical rotation of synthetic cis-211A ([α]D25 −11.5 (c 0.2, CHCl3)) with the reported
value ([α]D −11.7 (c 1.0, CHCl3)) [23]. Interestingly, cis-195A and cis-211A were both isolated from the same poison frog, Oophaga (Dendrobates) pumilio (Dendrobatidae) from Panama; however, the absolute stereochemistry of the parent decahydroquinoline nuclei of
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Nicotinic ACh receptors are ligand-gated cation channels [42,43]. Homomeric α7and heteromeric α4β2-pentamers are the major subtypes of nicotinic receptors found
in the central nervous system [44]. It has been reported that (−)-cis-195A, a natural cisdecahydroquinoline alkaloid (formerly referred to as Pumiliotoxin C), blocks ganglionic
nicotinic ACh receptors in pheochromocytoma PC12 cells [45] and that the synthetic analog
(+)-cis-195A is more potent than (−)-cis-195A at inhibiting nicotinic receptor activity [3].
Here, we examined the effects of ent-cis-195A, cis-211A, and 6-epi-211A on α7- and α4β2nicotinic ACh receptors ectopically expressed in Xenopus oocytes. If the criterion for partial
inhibition by an alkaloid is defined as a ≥ 20% decrease in the peak amplitude of AChelicited currents, then ent-cis-195A (1–10 µM) showed no apparent inhibitory effects on
α7- and α4β2-receptor-mediated currents (Figure 3A,B). cis-211A and 6-epi-211A at 10
µM partially inhibited α7-receptor-mediated currents by 38% and 31%, respectively, while
both alkaloids at 10 µM showed negligible effects on α4β2-receptor-mediated currents
(Figure 3C–F). Analysis of their structure–activity relationship suggested that the 6-hydroxy
moiety of cis-211A and 6-epi-211A might contribute to the partial blockade of α7-nicotinic
ACh receptors. The ligand-binding assays showed that none of these alkaloids affected
[3 H]nicotine and [3 H]methyllycaconitine binding to rat whole brain membranes (data not
shown). Therefore, cis-211A and 6-epi-211A were believed to act as noncompetitive blockers of α7-nicotinic receptors, although they were less potent and not as highly selective.
Neuronal nicotinic ACh receptors play a role in cerebral and retinal physiology. The
blood–brain barrier (BBB) and inner blood–retinal barrier (BRB) directly segregate the brain
and retina, respectively, from the circulating blood. It has been reported that putative
nicotine- and verapamil-sensitive cationic drug transport systems at the BBB and inner
BRB, respectively, are involved in the facilitative distribution of their substrates to the
central nervous system [46,47]. To evaluate the recognition of ent-cis-195A and cis-211A
as substrates for these cationic drug transport systems, we performed an inhibition study
using conditionally immortalized rat BBB and inner BRB model cells, known as TR-BBB13
and TR-iBRB2 cells [48,49]. As shown in Table 1, ent-cis-195A exhibited an inhibitory effect
on [3 H]nicotine transport into TR-BBB13 cells and [3 H]verapamil transport into TR-iBRB2
cells by more than 40%. In addition, the presence of cis-211A significantly attenuated
[3 H]nicotine and [3 H]verapamil uptake by TR-BBB13 and TR-iBRB2 cells, respectively,
by at least 29%. These results suggest that ent-cis-195A and cis-211A are recognized by
the cationic drug transport systems at the BBB and inner BRB. It is possible that these
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Neuronal nicotinic ACh receptors play a role in cerebral and retinal physiology. The

Table 1. Inhibitory effects of ent-cis-195A and cis-211A on [3 H]nicotine uptake by TR-BBB13 cells and
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[3 H]verapamil uptake by TR-iBRB2 cells.
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100 ± 5
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±
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*
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±
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*
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inner
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divergent process from the key and common intermediate 11. The absolute stereochemistry
of natural cis-211A was determined to be 2R, 4aR, 5R, 6S, and 8aS by comparison with
the data obtained from our total synthesis. The inhibitory effects of ent-cis-195A, cis-211A,
and 6-epi-211A on nicotinic ACh receptors were also investigated. The results showed
that cis-211A and 6-epi-211A had better inhibitory effects on the α7-receptor than that of
ent-cis-195A, and none of the compounds showed inhibitory effects on the α4β2-receptor
at the same concentration. These results suggested that cis-211A and 6-epi-211A could be
applied as important tools for studying the brain and nervous system. More interestingly,
the absolute configuration of the decahydroquinoline nuclei of cis-211A was a mirror image
of that of cis-195A, even though both alkaloids were isolated from Oophaga (Dendrobates)
pumilio from Panama.
3. Materials and Methods
3.1. Chemistry
3.1.1. General Information
Chemicals were purchased from Sigma–Aldrich, Merck (Darmstadt, Germany), FUJIFILM Wako Chemicals (Osaka, JAPAN), Nacalai Tesque, Tokyo Chemical Industry (Tokyo,
Japan), and Kanto Chemical (Tokyo, Japan) and used without further purification. Col-
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umn chromatography was done on Cica silica gel 60N (spherical, neutral; particle size,
63–210 nm, Kanto Chemical), while thin-layer chromatography was performed using Merck
silica gel 60F254 plates. Melting points were taken on a Yanaco micromelting point apparatus and are uncorrected. The nuclear magnetic resonance (NMR) spectra were acquired in
the specified solvent in JEOL JNM-A400 (400 and 100 MHz for 1 H and 13 C, respectively) or
JEOL JNM-ECX500 (500 and 125 MHz for 1 H and 13 C, respectively). The chemical shifts
(δ) are reported in ppm downfield from TMS, and coupling constants (J) are expressed in
Hertz. IR spectra were measured with a JASCO FT/IR-460 Plus spectrophotometer (JASCO
Corp., Tokyo, Japan). The low-resolution and high-resolution mass spectra were obtained
with a Shimadzu GCMS-QP 500 mass spectrometer (Shimadzu Corp., Kyoto, Japan), JEOL
D-200, or JEOL AX505 mass spectrometer (JEOL Ltd., Tokyo, Japan) in the electron impact
mode at the ionization potential of 70 eV.
3.1.2. Synthesis of (6R)-2-Phenylsulfanyl-6-propyl-piperidine-1,2-dicarboxylic Acid
Dimethyl Ester (3)
To a stirred solution of 1 [39] (2.51 g, 10.39 mmol) in EtOAc (30 mL) was added 10%
Pd/C (30 mg), and the resulting mixture was hydrogenated at 1 atm for 16 h. The catalyst
was removed through a celite pad and washed with EtOAc (5 mL × 3). The filtrate and
washings were combined and evaporated to give 2, which was essentially pure and used
directly in the next step. To a stirred solution of 2 in THF (30 mL) was added a solution
of sodium bis(trimethylsilyl)amide (1.9 M in THF, 8.20 mL, 15.59 mmol) at −78 ◦ C, and
the reaction mixture was stirred at −78 ◦ C for 30 min. To the reaction mixture was added
a solution of diphenyl disulfide (3.40 g, 15.59 mmol) in THF (15 mL), and the resulting
mixture was stirred at 0 ◦ C for 30 min. The solvent was evaporated, and the residue was
chromatographed on SiO2 (50 g, acetone/n-hexane = 1/30) to give 3 (3.39 g, 9.66 mmol,
93% in 2 steps) as a yellow oil as a mixture of diastereomers.
1 H-NMR (400 MHz CDCl ) δ: 0.90 and 0.94 (3H, each t, J = 7.2 Hz), 1.28–1.79 (8H, m),
3
1.90–1.98 (1H, m), 2.26–2.38 (1H, m), 3.49 and 3.62 (3H, each s), 3.73 and 3.74 (3H, each s),
4.06–4.20 (1H, m), 7.29–7.35 (3H, m), 7.73–7.78 (2H, m).
3.1.3. Synthesis of (6R)-6-Propyl-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid Dimethyl
Ester (4)
To a stirred solution of 3 (1.27 g, 3.61 mmol) in CH2 Cl2 (12 mL) was added 2,6-lutidine
(0.84 mL, 9.03 mmol), and then mCPBA (70%, 1.50 g, 8.67 mmol) was added to the reaction
mixture in four portions in 15 min intervals at 0 ◦ C. The resulting mixture was stirred at
room temperature for 8 h. The reaction was quenched with 10% Na2 S2 O3 in sat. NaHCO3
(aq.) (25 mL), and the aqueous mixture was diluted with EtOAc. The layers were separated,
and the aqueous layer was extracted with EtOAc (5 mL × 3). The organic layer and extracts
were combined and washed with brine, 10% HCl (aq.), and brine, successively. The organic
layer was dried and evaporated to give a pale yellow oil, which was chromatographed
on SiO2 (20 g, acetone/n-hexane = 1/30) to give 4 (871 mg, 3.61 mmol, 100%) as pale
yellow oil.
1 H-NMR (400 MHz CDCl ) δ: 0.93 (3H, t, J = 7.3 Hz), 1.17–1.28 (1H, m), 1.37–1.58 (3H,
3
m), 1.69–1.76 (1H, m), 1.79–1.89 (1H, m), 2.15–2.22 (2H, m), 3.70 (3H, s), 3.76 (3H, s), 4.42
(1H, br), 6.06 (1H, t, J = 3.6 Hz); 13 C-NMR (125 MHz CDCl3 ) δ: 13.75, 19.10, 19.53, 25.70,
31.62, 50.99, 51.87, 52.85, 122.08, 129.87, 154.63, 165.56; IR (neat): 1231, 1275, 1330, 1442,
1714, 1733 cm−1 ; MS (EI): m/z 241 (M+ ); HRMS (EI) Calcd for C12 H19 NO4 241.1314 (M+ );
Found 241.1315; [α]D 19 −68.0 (c 1.00, CHCl3 ).
3.1.4. Synthesis of (2R, 3S, 6R)-6-Propyl-3-vinyl-piperidine-1,2-dicarboxylic Acid Dimethyl
ester (5)
To a stirred solution of CuI (1.31 g, 6.90 mmol) in Et2 O (15 mL) was added a solution
of vinyl lithium, prepared from tetravinyltin (0.61 mL, 3.45 mmol) and MeLi (1.13 M in
Et2 O, 12.20 mL, 13.80 mmol) in Et2 O (15 mL) at 0 ◦ C for 30 min, at −78 ◦ C, and the reaction
mixture was warmed to -35 ◦ C for 30 min. The reaction mixture was recooled to −78 ◦ C,
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and a solution of 4 (555 mg, 2.30 mmol) in Et2 O (7 mL) was added to the reaction mixture.
The resulting mixture was gradually warmed to 0 ◦ C and stirred at the same temperature
for 1 h. The reaction was quenched with sat. NH4 Cl (aq.) (30 mL). The aqueous mixture
was diluted with CH2 Cl2 (30 mL), and the resulting mixture was filtered. The filtrate was
separated, and the aqueous layer was extracted with CH2 Cl2 (10 mL × 3). The organic
layer and extracts were combined, dried, and evaporated to give a colorless oil, which was
chromatographed on SiO2 (20 g, acetone/n-hexane = 1/30) to give 5 (613 mg, 2.28 mmol,
99%) as a colorless oil.
1 H-NMR (400 MHz CDCl ) δ: 0.90 (3H, t, J = 7.0 Hz), 1.25–1.56 (6H, m), 1.78–1.92
3
(2H, m), 3.08 (1H, br), 3.71 (3H, s), 3.74 (3H, s), 4.17–4.18 (1H, m), 4.88 (1H, br), 5.09–5.15
(2H, m), 5.81 (1H, ddd, J = 17.1, 10.7, 6.4 Hz); 13 C-NMR (125 MHz CDCl3 ) δ: 13.86, 19.88,
21.03, 22.45, 34.59, 36.52, 50.96, 51.99, 52.75, 55.07, 115.16, 139.00, 157.08, 172.86; IR (neat):
1200, 1340, 1363, 1448, 1506, 1558, 1683, 1699, 1734 cm−1 ; MS (EI): m/z 269 (M+ ); HRMS (EI)
Calcd for C14 H23 NO4 269.1627 (M+ ); Found 269.1631; [α]D 25 +53.6 (c 1.00, CHCl3 ).
3.1.5. Synthesis of (2S, 3S, 6R)-2-Methoxycarbonylmethyl-6-propyl-3-vinyl-piperidine-1
-carboxylic Acid Methyl Ester (6)
To a stirred solution of 5 (428 mg, 1.59 mmol) in MeOH (6 mL) and H2 O (2 mL) was
added LiOH·H2 O (266 mg, 6.36 mmol), and the resulting mixture was refluxed for 2 h.
After cooling, MeOH was evaporated, and the residue was acidified with 10% HCl (aq.)
(5 mL). The aqueous mixture was extracted with EtOAc (3 mL × 5). The organic extracts
were combined, dried, and evaporated to give a yellow oil, which was used directly in
the next step. To a stirred solution of the above oil in THF (10 mL) were added ClCO2 Et
(0.18 mL, 1.91 mmol) and Et3 N (0.27 mL, 1.91 mmol) at 0 ◦ C, and the resulting mixture was
stirred at 0 ◦ C for 1 h. The reaction mixture was diluted with Et2 O (3 mL), and Et3 N·HCl
was filtered off. The filtrate was evaporated to give a yellow oil, which was used directly in
the next step. To a stirred solution of the above oil in Et2 O (10 mL) was added a solution of
CH2 N2 in Et2 O at 0 ◦ C, and the reaction mixture was stirred at room temperature for 16 h.
The solvent was evaporated to give a yellow oil, which was dissolved in MeOH (10 mL).
To the MeOH solution were added AgCO2 Ph (37 mg, 0.16 mmol) and Et3 N (0.45 mL,
3.18 mmol), and the resulting mixture was stirred at room temperature for 24 h. The
reaction mixture was diluted with Et2 O, and the insoluble material was filtered off. The
filtrate was evaporated to give a black oil, which was chromatographed on SiO2 (20 g,
EtOAc/n-hexane = 1/30) to give 6 (409 mg, 1.45 mmol, 91% in 4 steps) as a colorless oil.
1 H-NMR (400 MHz CDCl ) δ: 0.92 (3H, t, J = 7.3 Hz), 1.20-1.42 (4H, m), 1.43–1.52
3
(2H, m), 1.78–1.92 (2H, m), 2.32 (1H, br), 2.54 (1H, dd, J = 14.9, 4.8 Hz), 2.65 (1H, dd,
J = 14.9, 10.1 Hz), 3.66 (3H, s), 3.68 (3H, s), 4.12 (1H, br), 4.61 (1H, br), 5.06 (1H, dt, J = 10.6,
1.4 Hz), 5.09 (1H, dt, J = 17.2, 1.4 Hz), 5.84 (1H, ddd, J = 17.2, 10.6, 6.6 Hz); 13 C-NMR
(125 MHz CDCl3 ) δ: 13.96, 20.05, 20.32, 22.18, 37.46, 39.73, 39.90, 50.73, 50.92, 51.67, 52.62,
115.07, 140.04, 156.76, 171.64; IR (neat): 1101, 1363, 1443, 1696, 1740 cm−1 ; MS (EI): m/z
283 (M+ ); HRMS (EI) Calcd for C15 H25 NO4 283.1784 (M+ ); Found 269.1780; [α]D 19 −31.4
(c 1.00, CHCl3 ).
3.1.6. Synthesis of (2S, 3S, 6R)-2-[(Methoxy-methyl-carbamoyl)-methyl]-6-propyl-3-vinyl
-piperidine-1-carboxylic Acid Methyl Ester (7)
To a stirred solution of 6 (571 mg, 2.02 mmol) in MeOH (4.5 mL) and H2 O (1.5 mL)
was added LiOH·H2 O (338 mg, 8.06 mmol), and the resulting mixture was refluxed for
2 h. After cooling, MeOH was evaporated, and the residue was acidified with 10% HCl
(aq.) (3 mL). The aqueous mixture was extracted with EtOAc (3mL × 5). The organic
extracts were combined, dried, and evaporated to give a yellow oil, which was used
directly in the next step. To a stirred solution of the above oil in CH2 Cl2 (7 mL) was added
1,1-carbonyldiimidazole (457 mg, 2.82 mmol) at 0 ◦ C, and the reaction mixture was stirred
for 30 min. To the reaction mixture were added MeO(Me)NH·HCl (275 mg, 2.82 mmol)
and Et3 N (0.40 mL, 2.82 mmol) at 0 ◦ C, and the resulting mixture was stirred at room
temperature for 16 h. The solvent was evaporated, and the residue was chromatographed
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on SiO2 (10 g, acetone/n-hexane = 1/7) to give 7 (610 mg, 1.95 mmol, 97% in 2 steps) as a
colorless oil.
1 H-NMR (500 MHz CDCl ) δ: 0.91 (3H, t, J = 7.3 Hz), 1.16-1.43 (4H, m), 1.48 (2H,
3
q, J = 6.0 Hz), 1.76-1.92 (2H, m), 2.37 (1H, br), 2.53-2.56 (1H, m), 2.80 (1H, m), 3.12 (3H,
br), 3.65 (3H, s), 3.67 (3H, s), 4.12 (1H, br), 4.63 (1H, br), 5.04 (1H, dd, J = 10.7, 1.4 Hz),
5.07 (1H, dd, J = 17.2, 1.4 Hz), 5.84 (1H, ddd, J = 17.2, 10.7, 1.4 Hz); 13 C-NMR (125 MHz
CDCl3 ) δ: 13.96, 19.85, 20.26, 22.15, 29.20, 32.12, 37.36, 39.15, 50.20, 50.55, 52.51, 61.22, 114.82,
140.30, 156.75, 172.01; IR (neat): 1100, 1348, 1362, 1444, 1667, 1694, 1698 cm−1 ; MS (EI): m/z
312 (M+ ); HRMS (EI) Calcd for C16 H28 N2 O4 312.2049 (M+ ); Found 312.2046; [α]D 23 −36.0
(c 1.00, CHCl3 ).
3.1.7. Synthesis of (2S, 3S, 6R)-2-(2-Oxo-propyl)-6-propyl-3-vinyl-piperidine-1-carboxylic
Acid Methyl Ester (8)
To a stirred solution of 7 (188 mg, 0.60 mmol) in THF (3 mL) was added a solution
MeMgBr (0.91 M in THF, 0.97 mL, 0.72 mmol) at 0 ◦ C, and the resulting mixture was stirred
at 0 ◦ C for 1 h. The reaction was quenched with sat. NH4 Cl (aq.) (5 mL). The layers were
separated, and the aqueous layer was extracted with CH2 Cl2 (5 mL × 3). The organic
layer and extracts were combined, dried, and evaporated to give a colorless oil, which was
chromatographed on SiO2 (7 g, acetone/n-hexane = 1/7) to give 8 (160 mg, 0.60 mmol,
99%) as a colorless oil.
1 H-NMR (500 MHz CDCl ) δ: 0.93 (3H, t, J = 7.3 Hz), 1.19-1.62 (6H, m), 1.79–1.91
3
(2H, m), 2.18 (3H, s), 2.24 (1H, br), 2.59–2.63 (1H, dd, J = 12.0, 2.8 Hz), 2.70–2.79 (1H, dd,
J = 12.0, 8.4 Hz), 3.69 (3H, s), 4.12 (1H, br), 4.62-4.64 (1H, m), 5.07 (1H, dd, J = 10.6, 1.5 Hz),
5.09 (1H, dd, J = 17.2, 1.5 Hz), 5.86 (1H, ddd, J = 17.2, 10.6, 1.5 Hz); 13 C-NMR (125 MHz
CDCl3 ) δ: 13.97, 19.82, 20.29, 22.00, 29.86, 37.30, 39.59, 49.44, 50.00, 50.26, 52.56, 115.08,
140.07, 156.74, 206.60; IR (neat): 1102, 1277, 1361, 1407, 1443, 1640, 1694 cm−1 ; MS (EI): m/z
267 (M+ ); HRMS (EI) Calcd for C15 H25 NO3 267.1834 (M+ ); Found 267.1835; [α]D 19 −70.0
(c 1.00, CHCl3 ).
3.1.8. Synthesis of (2S, 3S, 6R)-3-Formyl-2-(2-oxo-propyl)-6-propyl-piperidine-1-carboxylic
Acid Methyl Ester (9)
To a stirred solution of 8 (368 mg, 1.38 mmol) in 1,4-dioxane (6 mL) and H2 O
(2 mL) was added 2,6-lutidine (0.32 mL, 2.75 mmol), OsO4 (2% aqueous solution, 1.7 mL,
0.14 mmol) and NaIO4 (1.18 g, 5.51 mmol) at 0 ◦ C, and the resulting mixture was stirred at
room temperature for 3 h. The reaction was quenched with 10% Na2 S2 O3 in sat. NaHCO3
(aq.) (10 mL), and the aqueous mixture was diluted with CH2 Cl2 . The layers were separated, and the aqueous layer was extracted with CH2 Cl2 (5 mL × 3). The organic layer
and extracts were combined; washed with brine, 10% HCl (aq.), and brine, successively;
dried; and evaporated to give a yellow oil, which was chromatographed on SiO2 (10 g,
acetone/n-hexane = 1/10) to give 9 (349 mg, 1.29 mmol, 94%) as a colorless oil.
1 H-NMR (500 MHz CDCl ) δ: 0.90 (3H, t, J = 7.3 Hz), 1.16–1.26 (1H, m), 1.26–1.36
3
(1H, m), 1.38–1.57 (4H, m), 1.74–1.82 (1H, m), 1.93–1.99 (1H, m), 2.17 (3H, s), 2.37 (1H, br),
2.70–2.80 (2H, m), 3.67 (3H, s), 4.06 (1H, br), 5.15 (1H, br), 9.66 (1H, s); 13 C-NMR (125 MHz
CDCl3 ) δ: 13.94, 14.37, 20.22, 23.39, 30.15, 36.61, 45.10, 48.19, 48.90, 49.93, 52.74, 156.29,
202.79, 206.29; IR (neat): 1100, 1328, 1354, 1447, 1684, 1694, 1717, 2873, 2957 cm−1 ; MS (EI):
m/z 269 (M+ ); HRMS (EI) Calcd for C14 H23 NO4 269.1627 (M+ ); Found 269.1629; [α]D 23
−114.8 (c 1.00, CHCl3 ).
3.1.9. Synthesis of (2R, 4aR, 8aS)-7-Oxo-2-propyl-3,4,4a,7,8,8a-hexahydro-2H-quinoline-1
-carboxylic Acid Methyl Ester (10c)
To a stirred solution of 9 (349 mg, 1.30 mmol) in benzene (30 mL) was added DBU
(0.78 mL, 5.18 mmol) and MS 4 Å (50 mg), and the resulting mixture was refluxed for 48 h.
After cooling, benzene was evaporated, and the residue was acidified with 10% HCl (aq.)
(5 mL). The aqueous mixture was extracted with EtOAc (3mL × 5). The organic extracts
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were combined, dried, and evaporated to give a brown oil, which was chromatographed on
SiO2 (25 g, EtOAc/n-hexane = 1/10) to give 10c (235 mg, 0.94 mmol, 72%) as a yellow oil.
1 H-NMR (500 MHz CDCl ) δ: 0.91 (3H, t, J = 7.2 Hz), 1.24–1.41 (2H, m), 1.44–1.55
3
(2H, m), 1.59 (1H, td, J = 10.0, 2.4 Hz), 1.67 (1H, tdd, J = 10.0, 4.8, 2.4 Hz), 1.73–1.78 (1H,
m), 1.78–1.83 (1H, m), 2.40–2.45 (1H, m), 2.61 (2H, br), 3.70 (3H, s), 4.25 (1H, br), 4.63 (1H,
br), 6.13 (1H, d, J = 9.7 Hz), 6.77 (1H, dd, J = 9.7, 5.7 Hz); 13 C-NMR (125 MHz CDCl3 )
δ: 13.88, 19.95, 20.24, 27.09, 36.53, 37.00, 40.30, 48.43, 49.73, 52.60, 128.64, 152.18, 156.04,
198.22; IR (neat): 771, 1089, 1115, 1246, 1275, 1314, 1444, 1685, 2934 cm−1 ; MS (EI): m/z
251 (M+ ); HRMS (EI) Calcd for C14 H21 NO3 251.1521 (M+ ); Found 251.1522; [α]D 24 +29.9
(c 1.00, CHCl3 ).
3.1.10. Synthesis of (2R, 4aR, 5R, 8aR)-5-Methyl-2-propyl-7-trifluoromethane-sulfonyloxy3,4,4a,5,8,8a-hexahydro-2H-quinoline-1-carboxylic Acid Methyl Ester (11)
To a stirred solution of CuI (147 mg, 0.77 mmol) in Et2 O (3 mL) was added a solution
of MeLi (1.17 M in Et2 O, 1.32 mL, 1.54 mmol) at −78 ◦ C, and the reaction mixture was
warmed to 0 ◦ C for 30 min. The reaction mixture was recooled to −78 ◦ C, and a solution
of 10c (97 mg, 0.39 mmol) in Et2 O (3 mL) was added to the reaction mixture. The reaction
mixture was gradually warmed to 0 ◦ C, and then a solution of Comins’ reagent (303 mg,
0.77 mmol) in Et2 O (3 mL) was added to the reaction mixture. The resulting mixture was
stirred at room temperature for 2 h, and the reaction was quenched with sat. NH4 Cl (aq.)
(5 mL). The aqueous mixture was diluted with CH2 Cl2 (5 mL), and the resulting suspension
was filtered. The filtrate was separated, and the aqueous layer was extracted with CH2 Cl2
(3 mL × 3). The filtrate and extracts were combined, dried, and evaporated to give a
colorless oil, which was chromatographed on SiO2 (10 g, acetone/n-hexane = 1/50) to give
11 (144 mg, 0.36 mmol, 94%) as a colorless oil.
1 H-NMR (400 MHz CDCl ) δ: 0.90 (3H, t, J = 7.2 Hz), 1.12 (3H, d, J = 7.2 Hz), 1.19–1.39
3
(4H, m), 1.39–1.50 (1H, m), 1.50–1.72 (4H, m), 2.26 (1H, t, J = 6.0 Hz), 2.50 (2H, br), 3.69 (3H,
s), 4.10 (1H, br), 4.50 (1H, br), 5.66 (1H, d, J = 6.0 Hz); 13 C-NMR (100 MHz CDCl3 ) δ: 13.83,
19.15, 20.68, 21.49, 27.88, 29.67, 35.23, 38.04, 40.26, 46.91, 50.41, 52.63, 118.45 (q, J = 318.5 Hz),
121.19, 144.70, 156.65; IR (neat): 1144, 1209, 1246, 1419, 1445, 1699, 2936, 2959 cm−1 ; MS (EI):
m/z 399 (M+ ); HRMS (EI) Calcd for C16 H24 F3 NO5 S 399.1327 (M+ ); Found 399.1337; [α]D 23
+58.6 (c 1.35, CHCl3 ).
3.1.11. Synthesis of (2R, 4aR, 5R, 8aR)-5-Methyl-2-propyl-octahydro-quinoline-1-carboxylic
Acid Methyl Ester (12)
To a stirred solution of 11 (60 mg, 0.15 mmol) in MeOH (3 mL) was added 20%
Pd(OH)2 /C (5 mg), and the resulting mixture was hydrogenated at 1 atm for 16 h. The
catalyst was removed through a celite pad and washed with MeOH (3 mL × 3). The
filtrate and washings were combined and evaporated to give a pale yellow oil, which was
chromatographed on SiO2 (8 g, acetone/n-hexane = 1/30) to give 12 (33 mg, 0.13 mmol,
88%) as a colorless oil.
1 H-NMR (500 MHz CDCl ) δ: 0.90 (3H, t, J = 7.2 Hz), 1.06 (3H, d, J = 6.9 Hz), 1.17–1.68
3
(14H, m), 1.79–1.88 (2H, m), 3.70 (3H, s), 4.06 (1H, br), 4.22 (1H, br); 13 C-NMR (125 MHz
CDCl3 ) δ: 14.17, 19.41, 20.41, 20.72, 21.36, 26.82, 28.19, 28.57, 34.61, 37.81, 42.19, 49.81, 50.49,
52.36, 156.65; IR (neat): 1303, 1317, 1443, 1695, 2864, 2929, 2955 cm−1 ; MS (EI) m/z 253
(M+ ); HRMS (EI) Calcd for C15 H27 NO2 253.2042 (M+ ); Found 253.2043; [α]D 17 -20.2 (c 1.00,
CHCl3 ).
3.1.12. Synthesis of (2R, 4aR, 5R, 8aR)-5-Methyl-2-propyldecahydroquinoline
(ent-cis-195A)
To a stirred solution of 12 (42 mg, 0.17 mmol) in CHCl3 (3 mL) was added NaI
(197 mg, 1.32 mmol) and TMSCl (0.10 mL, 0.83 mmol), and the resulting mixture was
heated to 50 ◦ C for 24 h. After cooling, the reaction was quenched with 10% Na2 S2 O3 in
sat. NaHCO3 (aq.) (3 mL), and aqueous mixture was extracted with CH2 Cl2 (2 mL × 10).
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The organic extracts were combined, dried, and evaporated to give a pale yellow oil, which
was chromatographed on SiO2 (3 g, MeOH/CH2 Cl2 = 1/20) to give ent-cis-195A (30 mg,
0.15 mmol, 88%) as a pale yellow oil. ent-cis-195A. HCl was obtained in quantitative yield
by treatment with HCl (ca. 1 mol/L in Et2 O) followed by evaporation.
ent-cis-195A: 1 H-NMR (400 MHz CDCl3 ) δ: 0.83 (3H, d, J = 6.6 Hz), 0.90 (3H, t,
J = 7.0 Hz), 0.95–1.02 (1H, m), 1.03–1.14 (2H, m), 1.25–1.49 (8H, m), 1.52–1.70 (4H, m), 1.79–
1.90 (1H, m), 1.90–1.97 (1H, m), 2.53 (1H, dtd, J = 11.4, 5.8, 2.8 Hz), 2.84 (1H, q, J = 2.8 Hz);
13 C-NMR (100 MHz CDCl ) δ: 14.30, 19.14, 19.91, 21.21, 26.99, 27.24, 27.35, 33.28, 35.88,
3
39.59, 42.49, 55.96, 57.72; IR (neat): 857, 890, 962, 1024, 1044, 1081, 1124, 1167, 1256, 1317,
1348, 1380, 1451, 1734, 2803, 2873, 2935 cm−1 ; MS (EI) m/z 195 (M+ ); HRMS (EI) Calcd for
C13 H25 N 195.1987 (M+ ); Found 195.1985; ent-cis-195A. HCl: [α]D 20 +12.7 (c 0.35, MeOH).
The 1 H- and 13 C-NMR spectra and optical rotation of the synthetic sample were
identical with those of the literature data.
1 H-NMR (500 MHz CDCl ) δ: 0.83 (3H, d, J = 6.6 Hz), 0.90 (3 H, t, J = 7.0 Hz), 0.94–1.03
3
(1H, m), 1.05–1.14 (2H, m), 1.22–1.49 (9H, m), 1.50–1.71 (4H, m), 1.77–1.90 (1H, m), 1.90–1.99
(1H, m), 2.53 (1H, dtd, J = 11.4, 5.8, 2.7 Hz), 2.84 (1H, q, J = 2.8 Hz); 13 C-NMR (75 MHz
CDCl3 ) δ: 14.5 (CH3 ), 19.3 (CH2 ), 20.1 (CH3 ), 21.4 (CH2 ), 27.2 (CH2 ), 27.54 (CH), 27.55
(CH2 ), 33.6 (CH2 ), 36.1 (CH2 ), 39.9 (CH2 ), 42.8 (CH), 56.1 (CH), 57.9 (CH); ent-cis-195A. HCl:
[α]D 20 +12.9 (c 0.36, MeOH) [22].
3.1.13. Synthesis of (2R, 4aR, 5R, 8aR)-5-Methyl-2-propyl-3,4,4a,5,8,8a-hexahydro-2Hquinoline-1-carboxylic Acid Methyl Ester (13)
To a stirred solution of 11 (144 mg, 0.36 mmol) in THF (3 mL) was added PPh3 (7 mg,
0.03 mmol) and Pd(OAc)2 (3 mg, 0.01 mmol) at room temperature, and the reaction mixture
was heated to 25 ◦ C for 10 min. A solution of Et3 N (0.11 mL, 0.81 mmol) and formic acid
(0.03 mL, 0.80 mmol) in THF (1 mL) was added to the reaction mixture, and the resulting
mixture was refluxed for 18 h. The reaction was quenched with brine (5 mL). The layers
were separated, and the aqueous layer was extracted with CH2 Cl2 (3 mL × 3). The organic
layer and extracts were combined, dried, and evaporated to give a colorless oil, which was
chromatographed on SiO2 (8 g, acetone/n-hexane = 1/50) to give 13 (85 mg, 0.36 mmol,
100%) as a colorless oil.
1 H-NMR (400 MHz CDCl ) δ: 0.89 (3H, t, J = 7.2 Hz), 1.05 (3H, d, J = 6.4 Hz), 1.23-1.66
3
(9H, m), 2.03 (1H, m), 2.15 (2H, m), 3.67 (3H, s), 4.07 (1H, br), 4.35 (1H, br), 5.44-5.53 (2H,
m); 13 C-NMR (100 MHz CDCl3 ) δ: 14.02, 20.77, 21.96, 22.42, 27.34, 28.21, 29.67, 37.03, 41.33,
47.11, 50.53, 52.33, 122.82, 130.53, 156.39; IR (neat): 1093, 1304, 1320, 1444, 1695, 2871, 2930,
2955 cm−1 ; MS (EI) m/z 251 (M+ ); HRMS (EI) Calcd for C15 H25 NO2 251.1885 (M+ ); Found
251.1877; [α]D 23 +57.4 (c 0.90, CHCl3 ).
3.1.14. Synthesis of (2R, 4aR, 5R, 6R, 8aR)-6-Hydroxy-5-methyl-2-propyl-octahydroquinoline-1-carboxylic Acid Methyl Ester (15)
To a stirred solution of 13 (18 mg, 0.08 mmol) in toluene (1.5 mL) was added BH3 ·SMe2
(0.02 mL, 0.23 mmol) at 0 ◦ C. The reaction mixture was stirred at room temperature for
24 h and then cautiously quenched with 10% NaOH (0.25 mL) at 0 ◦ C, followed by the
slow addition of H2 O2 (30%, 0.25 mL) at 0 ◦ C. The reaction mixture was stirred at room
temperature for 24 h. The layers were separated, and the aqueous layer was extracted with
CH2 Cl2 (3 mL × 3). The organic layer and extracts were combined, dried, and evaporated
to give a colorless oil, which was chromatographed on SiO2 (5 g, acetone/n-hexane = 1/10)
to give 15 (10 mg, 0.04 mmol, 50%) as a colorless oil and the inseparable mixture of alcohols
16 and 17 (9 mg, 0.03 mmol, 45%) as a colorless oil.
15: 1 H-NMR (400 MHz CDCl3 ) δ: 0.91 (3H, t, J = 7.6 Hz), 1.05 (3H, d, J = 7.6 Hz),
1.20-1.26 (1H, m), 1.28-1.36 (2H, m), 1.46–1.68 (7H, m), 1.78 (1H, qdd, J = 14.3, 3.9, 2.8 Hz),
1.88 (1H, qd, J = 7.6, 1.7 Hz), 2.01 (1H, qd, J = 13.2, 3.9 Hz), 2.28 (1H, qd, J = 13.6, 3.2 Hz),
3.67 (3H, s), 4.02-4.10 (1H, m), 4.18-4.25 (1H, m); 13 C-NMR (100 MHz CDCl3 ) δ: 14.05, 18.89,
20.56, 22.77, 28.35, 28.64, 29.68, 37.33, 41.32, 41.87, 49.86, 50.51, 52.32, 70.97, 156.69; IR (neat):
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1319, 1447, 1456, 1670, 1697, 2872, 2934, 2957 cm−1 ; MS (EI) m/z 269 (M+ ); HRMS (EI) Calcd
for C15 H27 NO3 269.1991 (M+ ); Found 269.1990; [α]D 25 -17.1 (c 0.80, CHCl3 ).
3.1.15. Synthesis of (2R, 4aR, 5R, 8aR)-5-Methyl-6-oxo-2-propyl-octahydro-quinoline-1
-carboxylic Acid Methyl Ester (19)
To a stirred solution of 15 (46 mg, 0.17 mmol) in CH2 Cl2 (1.5 mL) and sat. NaHCO3
(aq.) (1.5 mL) was added NaOCl·5H2 O (55 mg, 0.34 mmol) and AZADOL® (0.3 mg,
0.0017 mmol) at 0 ◦ C, and the resulting mixture was stirred at room temperature for 1 h.
The layers were separated, and the aqueous layer was extracted with CH2 Cl2 (1 mL × 3).
The organic layer and extracts were combined, dried, and evaporated to give a yellow oil,
which was chromatographed on SiO2 (8 g, acetone/n-hexane = 1/5) to give 19 (43 mg,
0.16 mmol, 98%) as pale yellow oil.
1 H-NMR (400 MHz CDCl ) δ: 0.88 (3H, t, J = 6.8 Hz), 1.24 (3H, d, J = 7.6 Hz), 1.26–1.69
3
(8H, m), 1.76–1.84 (1H, m), 1.92–2.00 (1H, m), 2.06 (1H, qd, J = 12.8, 4.8 Hz), 2.16–2.22 (1H,
m), 2.26-2.33 (1H, m), 2.60 (1H, td, J = 14.8, 6.8 Hz), 3.69 (3H, s), 4.05–4.12 (1H, m), 4.58–4.61
(1H, m); 13 C-NMR (100 MHz CDCl3 ) δ: 13.99, 17.20, 20.53, 21.91, 27.40, 27.53, 29.68, 36.94,
37.45, 43.75, 48.89, 50.12, 50.45, 52.58, 156.57, 213.93; IR (neat): 1093, 1133, 1189, 1244, 1275,
1312, 1348, 1409, 1444, 1699, 1717, 2855, 2929, 2954 cm−1 ; MS (EI) m/z 267 (M+ ); HRMS (EI)
Calcd for C15 H25 NO3 267.1834 (M+ ); Found 267.1834; [α]D 25 -21.4 (c 0.50, CHCl3 ).
3.1.16. Synthesis of (2R, 4aR, 5R, 6S, 8aR)-6-Hydroxy-5-methyl-2-propyl-octahydroquinoline-1-carboxylic Acid Methyl Ester (16)
To a stirred solution of 19 (18 mg, 0.07 mmol) in THF (2 mL) was added a solution
of Super-Hydride® (1.0 M in THF, 0.20 mL, 0.20 mmol) at 0 ◦ C, and the resulting mixture
was stirred at room temperature for 1 h. The reaction was quenched with sat. NH4 Cl
(aq.) (2 mL). The layers were separated, and the aqueous layer was extracted with CH2 Cl2
(1 mL × 3). The organic layer and extracts were combined, dried, and evaporated to give a
colorless oil, which was chromatographed on SiO2 (5 g, acetone/n-hexane = 1/5) to give 16
(16 mg, 0.06 mmol, 89%) as a colorless oil and 15 (2 mg, 0.01 mmol, 11%) as a colorless oil.
1 H-NMR (400 MHz CDCl ) δ: 0.91 (3H, t, J = 7.2 Hz), 1.06 (3H, d, J = 7.2 Hz), 1.23–1.71
3
(13H, m), 1.83 (1H, qd, J = 13.6, 2.8 Hz), 1.99 (1H, t, J = 6.0 Hz), 3.68 (3H, s), 4.02–4.11 (1H,
m), 4.19–4.29 (1H, m); 13 C-NMR (100 MHz CDCl3 ) δ: 12.22, 14.03, 20.58, 21.03, 28.12, 28.64,
29.68, 37.58, 40.53, 43.06, 48.75, 50.33, 52.38, 68.66, 156.63; IR (neat): 1097, 1319, 1448, 1670,
2870, 2932, 2955 cm−1 ; MS (EI) m/z 269 (M+ ); HRMS (EI) Calcd for C15 H27 NO3 269.1991
(M+ ); Found 269.1990; [α]D 25 −16.5 (c 0.50, CHCl3 ).
3.1.17. Synthesis of (2R, 4aR, 5R, 6S, 8aR)-5-Methyl-2-propyldecahydroquinoline-6-ol
(cis-211A)
To a stirred solution of 16 (15 mg, 0.06 mmol) in MeCN (2 mL) was added NaI (67 mg,
0.45 mmol) and TMSCl (0.04 mL, 0.28 mmol), and the resulting mixture was refluxed for 1 h.
After cooling, the reaction was quenched with 10% Na2 S2 O3 in sat. NaHCO3 (aq.) (2 mL).
The layers were separated, and the aqueous layer was extracted with CH2 Cl2 (1 mL × 10).
The organic layer and extracts were combined, dried, and evaporated to give a pale yellow
oil, which was chromatographed on SiO2 (3 g, MeOH/CH2 Cl2 = 1/5) to give cis-211A
(13 mg, 0.06 mmol, 100%) as pale yellow oil.
1 H-NMR (400 MHz CDCl ) δ: 0.90 (3H, t, J = 6.4 Hz), 0.95 (3H, d, J = 6.8 Hz), 1.10–1.18
3
(2H, m), 1.27–1.45 (6H, m), 1.54–1.66 (3H, m), 1.80–1.87 (1H, m), 1.91–2.03 (2H, m), 2.06–2.15
(1H, m), 2.53–2.62 (1H, m), 2.89 (1H, br), 3.83 (1H, br); 13 C-NMR (100 MHz CDCl3 ) δ: 14.22,
15.82, 19.09, 26.37, 26.45, 28.08, 29.68, 31.02, 34.55, 39.09, 55.94, 57.95, 72.11; IR (neat): 753,
812, 883, 946, 997, 1029, 1100, 1158, 1191, 1257, 1317, 1339, 1376, 1444, 2806, 2879, 2934,
3659 cm−1 ; MS (EI) m/z 211 (M+ ); HRMS (EI) Calcd for C13 H25 NO 211.1936 (M+ ); Found
211.1943; [α]D 25 −11.5 (c 1.00, CHCl3 ).
The 1 H- and 13 C-NMR spectra and optical rotation of the synthetic sample were
identical with those of the literature data.
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(400 MHz CDCl3 ) δ: 0.90 (3H, t), 0.95 (3H, d), 1.06–1.16 (2H, m), 1.29–1.43
(6H, m), 1.56–1.67 (3H, m), 1.81–1.87 (1H, m), 1.91–2.03 (2H, m), 2.06–2.15 (1H, m), 2.53–2.61
(1H, m), 2.88 (1H, br), 3.82 (1H, br); 13 C-NMR (100 MHz CDCl3 ) δ: 14.3, 15.8, 19.1, 26.7,
26.8, 26.9, 28.9, 31.1, 34.9, 39.3, 55.8, 57.8, 72.3; [α]D 25 -11.7 (c 1.00, CHCl3 ) [23].
3.1.18. Synthesis of (2R, 4aR, 5R, 6R, 8aR)-5-Methyl-2-propyldecahydroquinoline-6-ol
(6-epi-211A)
To a stirred solution of 15 (18 mg, 0.07 mmol) in MeCN (2 mL) was added NaI (80 mg,
0.54 mmol) and TMSCl (0.04 mL, 0.33 mmol), and the resulting mixture was refluxed for 1 h.
After cooling, the reaction was quenched with 10% Na2 S2 O3 in sat. NaHCO3 (aq.) (2 mL).
The layers were separated, and the aqueous layer was extracted with CH2 Cl2 (1 mL × 10).
The organic layer and extracts were combined, dried, and evaporated to give a pale yellow
oil, which was chromatographed on SiO2 (3 g, MeOH/CH2 Cl2 = 1/5) to give 6-epi-211A
(10 mg, 0.05 mmol, 72%) as pale yellow oil.
1 H-NMR (400 MHz CDCl ) δ: 0.95 (3H, t, J = 7.2 Hz), 1.03-1.05 (1H, m), 1.07 (3H,
3
d, J = 6.0 Hz), 1.31–1.60 (5H, m), 1.68–1.82 (2H, m), 1.87-2.08 (4H, m), 2.14-2.20 (1H, m),
2.36–2.40 (1H, m), 3.11 (1H, m), 3.29 (1H, br), 3.34 (1H, td, J = 9.2, 3.6 Hz); 13 C-NMR
(100 MHz CDCl3 ) δ: 13.84, 15.11, 19.01, 23.91, 25.14, 27.48, 28.89, 35.47, 36.00, 39.18, 57.06,
59.69, 74.85; IR (neat): 1375, 1456, 1636, 1647, 2866, 2926, 2955, 3647 cm−1 ; MS (EI) m/z
211 (M+ ); HRMS (EI) Calcd for C13 H25 NO: 211.1936 (M+ ); Found 211.1928; [α]D 20 −5.3
(c 0.4, CHCl3 )
3.2. Electrophysiological Recording of Nicotinic ACh Receptor-Mediated Current in
Xenopus Oocytes
Xenopus oocytes expressing recombinant mouse α7- and α4β2-nicotinic ACh receptors
were prepared by injection of the plasmid containing respective subunit cDNAs (provided
by Dr. J. A. Stitzel, University of Michigan Medical Center), according to the protocols
described previously [29]. The oocytes were cultured at 19 ◦ C for 3 to 6 days in 50%
Leibovitz’s L-15 Medium (11415064, Thermo Fisher Scientific, Waltham, MA, USA, pH
7.5) containing 1 µg/mL insulin and 100 µg/mL gentamicin (078-06061, Fujifilm Wako
Pure Chemical Corp., Osaka, Japan). Two-electrode voltage-clamp recordings were then
performed, as described previously [29]. In brief, an oocyte was placed in a 300 µL tube-like
chamber where Ringer solution (82.5 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl2 , 1 mM MgCl2 ,
and 5 mM HEPES, pH 7.4) containing 1 µM atropine (A0257, Sigma–Aldrich, MA, USA)
was perfused at a rate of 15 mL/min. Membrane potential was held at −60 mV, and
currents were measured using a GeneClamp 500 amplifier, Digidata1322A, and pClamp9
software (Axon Instruments, Union City, CA, USA). The oocyte was pretreated with an
alkaloid for 3 min and then treated with ACh (011-00592, Fujifilm Wako Pure Chemical)
for 5 s. Each solution was rapidly switched by using a three-way valve (AG41-02-2-DAC100V Multilex Valve, CKD Corp., Aichi, Japan). To analyze the effects of alkaloids,
current response to ACh in the presence of alkaloid was normalized to control response
(i.e., current elicited by ACh (100 µM for α7 and 1 µM for α4β2) alone)) in each oocyte and
then averaged.
3.3. Ligand-Binding Assays
The [3 H]nicotine and [3 H]methyllycaconitine binding assays using membrane suspensions from whole rat brain (excluding cortex and cerebellum) were performed as described
previously [50].
3.4. In Vitro Effect of the Compound on the Transport of Cationic Compounds at the BBB and
Inner BRB
As model cells of the rat BBB and inner BRB, TR-BBB and TR-iBRB2 cells were
utilized [48,49]. These cells were cultured following the previous manuscript [51] and
seeded onto collagen type I-coated 24-well plate (Corning, Kennebunk, ME, USA) at a
density of 5 × 104 cells/cm2 . The cells were cultured for 2 days and then washed with
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extracellular fluid buffer (122 mM NaCl, 25 mM NaHCO3 , 3 mM KCl, 1.4 mM CaCl2 ,
1.2 mM MgSO4 , 0.4 mM K2 HPO4 , 10 mM D-glucose, 10 mM 2-[4-(2-hydroxyethyl)-1piperazinyl]ethanesulfonic acid-NaOH, pH 7.4) at 37 ◦ C. The extracellular fluid buffer
containing [3 H]nicotine (85 Ci/mmol; American Radiolabeled Chemicals, St. Louis, MO,
USA) or [3 H]verapamil (80 Ci/mmol; American Radiolabeled Chemicals) at a concentration
of 0.5 µCi/mL in the absence or presence of test compounds at 200 µM with 1.0% DMSO
was applied to the cells and incubated at 37 ◦ C for designed time ([3 H]nicotine, 10 sec;
[3 H]verapamil, 3 min). After the uptake reaction, the cells were rinsed with the extracellular
fluid buffer at 4 ◦ C and solubilized in 1 N NaOH. The solubilized solution was neutralized
with 1 N HCl. The 3 H-radioactivities derived from the cell-solubilized solution and reaction
buffer were measured using an AccuFLEX LSC-7400 liquid scintillation counter (Hitachi,
Kashiwa, Japan). Protein concentration in the solubilized solution was quantified by a DC
protein assay kit II (BIO-RAD, Hercules, CA, USA). The uptake activities were normalized
by the concentration of the radiolabeled compound in the transport buffer and the cellular
protein amount in each well. The data were expressed as the percentage of uptake activity
in the control group and mean ± S.E.M. Statistic difference was evaluated using a one-way
analysis of variance followed by Dunnett’s test.
Supplementary Materials: The NMR spectra (1 H-NMR,
available online.

13 C-NMR)

of all new compounds are
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